基于国医大师段富津豁痰宣痹理论的化痰通络颗粒治疗冠心病稳定型心绞痛(痰瘀互阻证)作用机制研究
Research on the Mechanism of Action of Huatan Tongluo Granules (Based on Master Physician Duan Fujin’s Theory of Resolving Phlegm and Unblocking Obstruction) in Treating Stable Angina Pectoris of Coronary Heart Disease (Syndrome of Phlegm-Stasis Intermingling)
DOI: 10.12677/tcm.2025.1411677, PDF,   
作者: 赵智博:黑龙江中医药大学研究生院,黑龙江 哈尔滨;陈会君:黑龙江中医药大学附属第二医院心内二科,黑龙江 哈尔滨
关键词: 冠心病稳定型心绞痛化痰通络颗粒痰瘀互阻豁痰宣痹理论Stable Angina Pectoris of Coronary Heart Disease Huatan Tongluo Granules Phlegm-Stasis Mutual Obstruction Theory of Expelling Phlegm and Diffusing Chest Impediment
摘要: 近年来,心血管疾病已成为全球健康的首要威胁,其中以冠心病稳定型心绞痛作为典型代表,发病率呈年轻化与普遍化趋势。现代医学认为其发病主要与冠状动脉粥样硬化导致的心肌氧供需求失衡有关,治疗以抗血小板聚集、血脂调控、血压管理及改善冠脉供血为主,但存在持续性差和不良反应等问题。中医则将其归类为“胸痹”范畴,认为病机为本虚标实、虚实夹杂,以气虚为本,痰浊、血瘀为标。基于国医大师段富津的豁痰宣痹理论,化痰通络颗粒在瓜蒌薤白半夏汤基础上化裁而来,兼顾祛痰化瘀与补气,通过多成分、多靶点的作用机制,有效改善冠心病稳定型心绞痛(痰瘀互阻证)的症状,为中医药治疗心血管疾病提供了新的思路和方法。
Abstract: In recent years, cardiovascular diseases have become a primary global health threat, with stable angina pectoris of Coronary Heart Disease (CHD) as a typical example showing a trend of increasing incidence among younger and broader populations. Modern medicine attributes its pathogenesis mainly to an imbalance between myocardial oxygen supply and demand caused by coronary atherosclerosis. Primary treatments include antiplatelet aggregation, lipid regulation, blood pressure management, and improving coronary blood supply. However, these approaches are often associated with issues such as poor adherence and adverse effects. In Traditional Chinese Medicine (TCM), this condition is categorized as ‘chest impediment’ (Xiong Bi). Its pathogenesis is considered a deficiency-excess complex, characterized by root deficiency and branch excess. Qi deficiency constitutes the root, while phlegm-turbidity and blood stasis form the branch manifestations. Based on the theory of expelling phlegm and diffusing chest impediment from Master of TCM Duan Fujin, Huatan Tongluo Granules are derived from the classic formula Gualou Xiebai Banxia Decoction. This formula simultaneously addresses the elimination of phlegm, dissolution of stasis, and supplementation of qi. Through a multi-component, multi-target mechanism of action, Huatan Tongluo Granules effectively alleviate symptoms in patients with stable angina pectoris of CHD (pattern of phlegm-stasis mutual obstruction). This provides a new perspective and methodology for treating cardiovascular diseases within the framework of TCM.
文章引用:赵智博, 陈会君. 基于国医大师段富津豁痰宣痹理论的化痰通络颗粒治疗冠心病稳定型心绞痛(痰瘀互阻证)作用机制研究 [J]. 中医学, 2025, 14(11): 4697-4702. https://doi.org/10.12677/tcm.2025.1411677

参考文献

[1] 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志, 2023, 38(6): 583-612.
[2] 董洁. 老年冠心病患者猝死的诱发因素分析和护理对策[J]. 现代医学与健康研究电子杂志, 2017, 1(7): 110.
[3] 和静, 房中则, 杨颖, 等. 血浆中脂质代谢分子与颈动脉粥样硬化斑块、传统心血管危险因素及膳食因素的关系[J]. 北京大学学报(医学版), 2024, 56(4): 722-728.
[4] 王建勋. 益肾活血解毒汤对CHD患者血清GM-CSF、IL-37、CRP影响的临床研究[D]: [硕士学位论文]. 合肥: 安徽中医药大学, 2017.
[5] 沈冲, 陆强, 高德全, 等. 探讨阿昔莫司联合阿托伐他汀钙片治疗高脂血症的疗效[J]. 中国老年保健医学, 2022, 20(3): 59-61.
[6] 张嵚垚, 马淑梅. 静脉注射尼可地尔对行经皮冠状动脉介入治疗的不稳定性心绞痛患者的心肌保护作用[J]. 实用药物与临床, 2020, 23(1): 38-42.
[7] 吕哲, 冯博, 崔山龙. 硝苯地平缓释片联合依那普利治疗老年冠心病合并高血压的临床疗效分析[J]. 系统医学, 2022, 7(21): 130-133.
[8] 徐伟东. 尼群地平治疗高血压冠心病28例疗效观察[J]. 吉林医学, 2013, 34(4): 682-683.
[9] 王传池, 杨燕, 吴珊, 等. 冠心病不同发展阶段中医证演变规律研究[J]. 中华中医药杂志, 2019, 34(5): 2101-2106.
[10] 刘田野. 吲达帕胺联合氨氯地平治疗高血压合并冠心病的临床疗效及其对患者血压和血脂的影响[J]. 临床合理用药杂志, 2018, 11(30): 4-5.
[11] 李冬方, 何小丽, 都基莎, 等. 黄芪多糖心血管药理作用研究概况[J]. 辽宁中医杂志, 2013, 40(3): 586-587.
[12] 孙鑫, 梁霄, 李娅兰, 等. 活血化瘀类中药通过调控细胞自噬防治心血管疾病的研究进展[J]. 中国药房, 2024, 35(16): 2048-2054.
[13] 许志亮, 卢健棋, 黄溥玮, 等. 基于数据分析中药降香治疗冠心病作用机制及药理研究进展[J]. 辽宁中医药大学学报, 2020, 22(10): 70-75.
[14] 苏真真, 张新庄, 李娜, 等. 利用网络药理学方法考察金振口服液抗呼吸道感染的作用机制[J]. 中国实验方剂学杂志, 2016, 22(17): 165-171.